Introduction
The opportunity to choose a specific prophylactic therapy for a patient depends upon the severity of the attacks and how these headaches alter the quality of life. Prophylactic treatment is usually recommended in the case of 3 or more severe attacks per month incompletely responding to symptomatic treatment and in the case of more than 4 days with headache per month.
The main goals for preventive agents in migraine treatment are to reduce the frequency and severity of migraine attacks and improve the quality of life. It is generally accepted that a good response to prophylactic treatment is at least a 50% reduction in the frequency or severity of migraine attacks. Others goals are to expand the knowledge of preventive treatments, to promote studies in this field, and to avoid the development of a chronic daily headache as well as symptomatic drug abuse or misuse [1] .
As for all therapeutic strategies, even the prophylactic drugs for migraine should undergo a careful evaluation of their benefit/risk ratio. This implies that each treatment should be used at the dosage with the least number of adverse drug reactions (ADRs) in order to reduce the number and severity of attacks for an adequate period until the treatment can be stopped.
The presence of any comorbid conditions should be considered in the choice of a preventive medication for migraine.
From evidence-based medicine to recommendations
Recommendations for the prophylactic treatment of migraine should be not just the simple sum of the findings of clinical trials from evidence-based papers, obtained from Medline, but also the result of the critical evaluation by a group of experts who discuss the results available in the literature, taking into account their own experiences. In fact, clinical reports may not be sufficient for giving a step approach to treatment choice, particularly for drugs not yet adequately evaluated, even if they are used by patients or prescribed by physicians [2] [3] [4] .
Management of pharmacological treatment
To minimize the risk and improve the patient's compliance, prophylactic treatment should be started at low doses, possibly as a monotherapy. Doses can be slowly increased until therapeutic goals are achieved in the absence of side effects. The treatment should be maintained for at least 3 months before stopping it. In fact, clinical benefit may take as long as 1-3 months after the onset of response. To use a monotherapy at adequate doses and for an adequate period of time is necessary in order to underscore the relationship between drug efficacy and side effects.
Long-acting or depot formulations can improve patient compliance. When pharmacological resistance appears, a new prophylactic treatment with another drug should be preceded by a washout period.
Drugs contraindicated for any comorbid conditions (i.e. beta-blockers in patients with asthma) and drugs that could worsen migraine (i.e. nifedipine for hypertension) should be avoided, when possible.
Particular attention should be devoted to drug-drug or drug-food interactions, and it should be remembered that many prophylactic treatments may cause teratogenic effects. Therefore, prophylactic treatment during pregnancy should be limited to special situations, and in these rare cases, drugs with the lowest risk to the fetus should be selected.
Patient recommendations
The main problem in preventive therapies is always patient compliance. The compliance in prolonged treatments is inversely related to the length of treatment and the number of pills taken every day. Therefore, when possible, the number of drugs taken should be reduced and the patients should be involved in the choice of their own treatment. Patients should be carefully informed about how and when to take drugs, and about the potential adverse effects. Another relevant point to address is the patient's expectations of the actual therapeutic efficacy of the drug, and about the impact of the treatment on the quality of life and disease evolution.
For the evaluation of the efficacy of the treatment, patients should be educated to follow a formal management plan and to carefully fill out headache diaries that record the frequency and duration of attacks, the severity of pain, the functional impairment, disability and the drugs taken as well as any adverse events. These parameters are necessary to assess the modifications in migraine due to preventive treatment.
Primary prevention of migraine
Migraine can be considered as a particular response of the human brain to a number of triggers, both internal and external. Such response is probably genetically determined. Migraine patients seem to present a lower threshold for attacks in certain brain areas compared with those of non-migraineurs. In this regard, the primary prophylaxis of migraine should be focused on identifying the triggers and carefully avoiding them by changing the patient's lifestyle. Therefore, patients should be provided a list of common triggers to avoid. Another easy method is encouraging patients to note all the migraine attacks and the potential triggers for each attack in their headache diary.
The most frequent trigger factors are listed in Table 1 . However, even a correct lifestyle cannot prevent all migraine attacks in all patients.
It has been hypothesized that migraine patients have a lowered threshold for trigger factors, perhaps genetically determined. So, a rational prophylactic treatment should be focused to enhance this threshold and this, together with the removal of trigger factors, when possible, should result in the reduction of the number and intensity of attacks.
Precipitating factors are those factors able to elicit a migraine attack, after a short time of exposure. They are not the cause of migraines. They often need cofactors to precipitate the attacks and, even in the same patients, one factor is not enough to always induce the attack.
One or more precipitating factors are reported in 64%-90% of patients with migraine, and these are more frequent in those with migraine without aura than with aura. The most frequent factors are stress and psychological tension.
A trivial trigger is considered food. Many people believe that by avoiding some specific foods it is possible to reduce the frequency of migraine attacks. Putative allergic factors are often considered responsible for migraine attacks, whereas, only in rare cases, a specific food directly causes migraine. From 20% to 52% of patients report that alcoholic drinks precipitate migraine, and conflicting data have been reported with respect to differences between beer or red and white wine. Also, some foods are involved as precipitating factors in percentages varying from 10% to 45%, namely: chocolate, cheese, some fruits, citrus fruits, fatty foods and fried foods. Peatfield [5] recorded 19% of patients reporting sensitivity to cheese, chocolate, or both, and 11% of patients sensitive to citrus fruits. The exact mechanism of these migraine attacks is unknown, although migraine is generally believed to be caused by a chemical reaction consisting in the release of serotonin from the intestinal wall, or by an enzymatic defect, and not by allergic reactions.
By contrast, fasting has been described to be a precipitating factor in 25% of children and in 40% of adults affected by migraine.
Menstruation is a common precipitating factor in 24%-64% of women suffering from migraine without aura. In fact, hormonal factors can be considered as both precipitating and predisposing factors.
Both too much or too little sleep as well as fatigue are believed to be precipitating factors.
Moreover, weather changes are often considered to be precipitating factors for migraine in a percentage ranging from 7% to 43%, and patients even say that they are able to predict the forecast. By contrast, specific studies did not show a relationship between migraine attacks and either weather conditions or barometric changes.
Glaring, blinding and psychedelic lights are also reported to be precipitating factors for migraine, and in a recent study these lights were recognized as precipitating factors only in migraine with aura [6] .
Other triggers could be angiographic procedures, head injuries, physical exercise, and altitude. By contrast, sexual activity does not seem able to cause a migraine attack.
Behavior modifications
The first recommendation for patients should be to avoid trigger factors. To obtain this result, patients need to recog-nize their specific trigger factors; therefore, it is necessary to carefully fill out the diary that should be evaluated at every medical visit.
When stress is identified as the main trigger factor, it is useful to begin a formal behavioral treatment program to avoid stressors, since pharmacological therapy alone is unable to control migraine attacks. For this purpose, muscle relaxation techniques, including biofeedback, are recommended. In some cases physical exercise can be useful to reduce stress.
Drug treatment should be used together with behavior modifications to obtain a significant reduction of migraine attacks and an improvement in the quality of life.
Re-evaluation of the diagnosis
The diagnosis should be re-evaluated when: -there is a case of high frequency of migraine attacks -there are changes in migraine characteristics (i.e. focal symptoms, variation of frequency, intensity or length of attacks, etc.) -there is a lack of effects after three treatments with different drugs -there is an analgesic abuse
Drugs for prophylactic treatment
A few drugs for the prophylactic treatment of migraine have been studied in adequate clinical trials according to evidence-based medicine (EBM) criteria. The level and quality of evidence for their use, and the overall recommendation level, are presented in Tables 2 and 3 respectively. Clinically relevant drug-drug interactions are given in Table 4 .
Beta-blockers
How beta-blockers can reduce attack frequency in migraneurs is not clear, although it is probably by acting on the central monoaminergic system and serotonin receptors. Not all these drugs are effective, and those used in migraine prophylaxis include atenolol, metoprolol, nadolol and propranolol . Beta-blockers are contraindicated in patients with chronic obstructive pulmonary disease, diabetes mellitus, heart failure and peripheral vascular diseases. There is a relative contraindication in pregnancy.
Atenolol and nadolol are excreted by the kidneys and show fewer adverse effects in the central nervous system (CNS). Failure of prophylactic treatment with one betablocker is not predictive of the activity of other beta-blockers, so that consecutive trials with these drugs are appropriate. Physicians should start with low doses and increase them slowly, if necessary.
When migraine attacks are controlled, doses can be reduced slowly. The abrupt suspension of beta-blockers can induce rebound effects both increasing migraine attacks and inducing adrenergic side effects and hypertension.
Calcium channel blockers
Calcium channel blockers act by modulating neurotransmission, inducing vasodilatation and exerting a cytoprotective effect by preventing the influx of calcium ions into the cells and reducing cell damage due to hypoxia. The therapeutic effects become evident only after some months of treatment, and are associated with a number of side effects. Among all available drugs of this class, the most used are flunarizine (level of evidence A, recommendation level I) and verapamil (level of evidence B, recommendation level II) . The efficacy of these drugs in reducing migraine attacks by at least 50% and improving the quality of life is comparable with that obtained by beta-blockers at least for flunarizine. Less consistent are the findings with nimodipine and nifedipine [78] [79] [80] [81] [82] .
Some calcium channel blockers are contraindicated in pregnancy, hypotension, heart failure, atrioventricular (AV) block, Parkinson's disease and depression (e.g. flunarizine) and in patients in therapy with beta-blockers and monoamine oxidase inhibitors (MAOI) (e.g. verapamil).
Serotonin antagonists
Pizotifen is one of the serotonin receptor antagonists with weak antihistaminic and cholinergic effects. Despite its effectiveness in migraine, with a clinical benefit in 50%-64% of the cases, it has side effects which include weight gain and asthenia (level of evidence A, recommendation level IIIb) [83] [84] [85] [86] . Methysergide is a semisynthetic ergometrine derivative with activity as 5-HT 1 and 5-HT 2 receptor antagonists. It has been shown to be active, particularly in cases with high frequency of attacks not responsive to treatment [86] . Contraindications include pregnancy, peripheral vascular disorders, severe arteriosclerosis, coronary artery disease, severe hypertension, thrombophlebitis or cellulitis of the legs, peptic ulcer disease, fibrotic disorders, lung diseases, connective tissue disease, liver or renal function impairment, valvular heart disease, cachexia, or serious infection. Methysergide can induce retroperitoneal fibrosis and pleural and heart valve fibrosis with an estimated incidence of 1 in 5000 treated patients. Therefore, it should be reserved for severe cases in which other migraine preventive drugs are not effective, taking carefully into account the risk-benefit ratio. Today this drug is not available in Italy.
Tricyclic antidepressants
Amitriptyline is useful in migraine, especially in patients with concomitant tension-type headache (level of evidence A, recommendation class I). The mechanism of action is not related to its antidepressant activity. Amitriptyline modulates monoaminergic pathways, by inhibiting the reuptake of both adrenaline and serotonin. Moreover, it functionally down-regulates β-adrenergic and serotonergic receptor expression in the central nervous system The effective dose varies [27, [87] [88] [89] [90] [91] , starting with an initial dose of 10 mg, per os, every night, to be increased by 10 mg per week, up to a maximum of 50 mg per day. High doses could be necessary in the case of concomitant depression.
A lower risk of developing asthenia and anticholinergic side effects has been observed for nortriptyline compared to amitriptyline (level of evidence C). The contraindications include: severe cardiac, liver, renal, prostatic and thyroid diseases, glaucoma, hypotension, convulsive disorders and concomitant use of MAOI.
Tricyclic antidepressants should be used with caution in elderly patients because of anticholinergic effects.
Selective serotonin-reuptake inhibitors
Few studies are available on the use of this class of drugs in the prophylaxis of migraine [92] [93] [94] [95] [96] [97] [98] . At the moment, there is no definitive evidence supporting the use of these drugs in preventing migraine attacks.
Alpha-2 agonists
The majority of the studies on the prophylactic treatment of migraine concern clonidine but failed to show more efficacy compared with placebo [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] . Negative results were also obtained with guanfacine [114] .
Antiepileptic drugs
Sodium valproate shows excellent results in preventing migraine in clinical trials (level of evidence A; recommendation level I) [115] [116] [117] [118] [119] [120] .
Care should be used when this drug is associated with acetylsalicylic acid (ASA) and warfarin, because of the possibility of bleeding. The main side effects are nausea, alopecia, tremors and weight gain; chronic use may induce liver damage, mostly in children. This drug is teratogenic and should not be administered to pregnant women.
Gabapentin, a GABAergic drug, has been shown to be effective in preventing migraine attacks [121, 122] . In a recent multicenter double-blind placebo-controlled study, this drug was significantly more effective than placebo in reducing the frequency of migraine attacks [122] . The more frequent adverse effects were somnolence and dizziness.
Topiramate and lamotrigine have been used with moderate efficacy in migraine prophylaxis [123] [124] [125] [126] [127] [128] [129] [130] . The most frequent side effects of topiramate were cognitive dysfunction, sedation, diarrhea, weight loss, and dizziness. Recently, it has been reported that after one month of therapy with topiramate, some patients reported an acute reduction of vision, myopia and acute narrow-angle glaucoma.
Lamotrigine showed less efficacy in preventing migraine without aura, whereas it was efficacious in preventing attacks in the case of a high frequency of migraine with aura crises [128] [129] [130] . The most frequent side effects were: rash (some fatal), fatigue, dizziness, headache, Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity reactions.
No recent studies have been carried out on carbamazepine as a prophylactic antimigraine drug and data are inconclusive about its efficacy [131, 132] .
Non-steroidal anti-inflammatory drugs
The main mechanism of action of non-steroidal antiinflammatory drugs (NSAIDs) is the inhibition of cyclooxygenase in both isoforms, whereas, even in the absence of inflammation, NSAIDs are active in reducing migraine pain (level of evidence B, recommendation level II). Among this class of drugs, acetylsalicylic acid, flurbiprofen, lornoxicam, mefenamic acid, ketoprofen and both naproxen and naproxen sodium show a discrete effectiveness in migraine prophylaxis [2, [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] [145] [146] . Both naproxen and naproxen sodium are useful in the prevention of menstrual migraine (level of evidence B; recommendation level II) [147, 148] .
NSAIDs should be used for intermittent prophylaxis in menstrual migraine and not for prolonged periods of time because of their gastric and intestinal side effects (level of evidence B) [149, 150] .
Dihydroergotamine
Dihydroergotamine in slow-release formulations at various doses was effective in preventing migraine attacks [151, 152] . Dihydroergokryptine also appeared to be an effective drug for the prophylaxis of migraine attacks [153] .
Lisuride
Lisuride has been proved to be effective and well-tolerated for migraine prophylaxis in some studies [154, 155] . In an open study, a reduction of more than 50% of attacks was observed in 61.4% of patients treated for a 3-month period, with good tolerance [154] .
Riboflavin
Riboflavin at high doses (up to 400 mg) showed good effectiveness in preventing migraine attacks [156] with a low rate of unwanted side effects, such as mild abdominal pain and diarrhea. This drug at these doses is not available in Italy.
Estrogens
Some clinical trials showed the efficacy of high doses of estradiol (1.5 mg/day in gel) in the prophylactic treatment of menstrual migraine. They have been demonstrated to significantly reduce the number of attacks [157, 158] . Lower doses (50 mg/day) were ineffective. Preliminary studies suggest a possible effectiveness of the association of estradiol with flumedroxone and methysergide [86] .
Tanacetum parthenium
The efficacy of feverfew in preventing migraine is not universally accepted. Some studies show a reduction in pain intensity and associated symptoms, whereas others show an increase in the frequency of attacks or no differences in comparison with placebo [159] [160] [161] [162] .
Magnesium
Magnesium showed efficacy in preventing migraine in three clinical trials [163] [164] [165] . 
